Technical Data
E3440-12
Epstein Barr Virus, Latent Membrane Protein 2A (EBV LMP2A, Human Herpes virus 4, HHV4, Latent Membrane Protein 2, LMP2, Terminal Protein)
Description:
Applications:
Suitable for use in Immunofluorescence, Immunoprecipitation, and Western Blot. Other applications not tested.

Recommended Dilution:
Western Blot: 1:100-1:1,000
Optimal dilutions to be determined by the researcher.

Hybridoma:
P3X63.Ag8.653 myeloma cells with spleen cells from Balb/c mice.

Storage and Stability:
May be stored at 4C for short-term only. For long-term storage and to avoid repeated freezing and thawing, add sterile 40-50% glycerol, aliquot and store at -20C. Aliquots are stable for at least 12 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
TypeIsotypeCloneGrade
MabIgG2a10C125Affinity Purified
SizeStorageShippingSourceHost
250ug-20CBlue IceRat
Concentration:
~1mg/ml
Immunogen:
Bacterial TrpE-LMP2A fusion protein
Purity:
Purified by Protein G affinity chromatography.
Form
Supplied as a liquid in PBS, pH 7.4, 0.09% sodium azide.
Specificity:
Recognizes latent membrane protein 2A (LMP2A) of Epstein-Barr virus (EBV).
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Fruehling, S. et al. (1996) Identification of latent membrane protein 2A (LMP2A) domains essential for the LMP2A dominant-negative effect on B-lymphocyte surface immunoglobulin signal transduction. J Virol. 70:6216 6226, 2. Fruehling, S. et al. (1998) Tyrosine 112 of latent membrane protein 2A is essential for protein tyrosine kinase loading and regulation of Epstein-Barr virus latency. J Virol. 72:7796 7806.